GLP1R and pancreatic neoplasm: A recent retrospective cohort study similarly showed that GLP-1R agonist use was associated with a lower risk of pancreatic cancer compared with use of several other antihyperglycemic drugs, including insulin, metformin, DPP4 inhibitors, SGLT2 inhibitors, sulfonylurea, or thiazolidinediones (TZDs) (53).